Challenging the standard of care in advanced melanoma: focus on pembrolizumab

References

• American Cancer SocietyCancer Facts & Figures 2017Atlanta, GAAmerican Cancer Society2017
   Google Scholar
• AtkinsMBKunkelLSznolMRosenbergSAHigh-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateCancer J Sci Am20006suppl 1S11S1410685652
   PubMed Web of Science ®Google Scholar
• AndersonCMBuzaidACLeghaSSSystemic treatments for advanced cutaneous melanomaOncology (Williston Park)1995911491158 discussion 1163–1164, 1167–11688703684
   PubMedGoogle Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• JohnLCoweyCLThe rapid emergence of novel therapeutics in advanced malignant melanomaDermatol Ther (Heidelb)20155315116926387031
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• AsciertoPAMcArthurGADrenoBcoBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF (V600) mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)J Transl Med2015132061
   Google Scholar
• RobertCKaraszewskaBSchachterJImproved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med20153721303925399551
   PubMed Web of Science ®Google Scholar
• PastorfideGCKibbiAGde RoaALImage analysis of stage 1 melanoma (1.00–2.50 mm): lymphocytic infiltrates related to metastasis and survivalJ Cutan Pathol19921953903971474192
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• FongLSmallEJAnti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatmentJ Clin Oncol200826325275528318838703
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• SchadendorfDHodiFSRobertCPooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanomaJ Clin Oncol201533171889189425667295
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• OkazakiTChikumaSIwaiYFagarasanSHonjoTA rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNat Immunol201314121212121824240160
   PubMed Web of Science ®Google Scholar
• NishimuraHNoseMHiaiHMinatoNHonjoTDevelopment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptorImmunity199911214115110485649
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919122931229712218188
   PubMed Web of Science ®Google Scholar
• FreemanGJLongAJIwaiYEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationJ Exp Med200019271027103411015443
   PubMed Web of Science ®Google Scholar
• DongYSunQZhangXPD-1 and its ligands are important immune checkpoints in cancerOncotarget2017822171218627974689
   PubMedGoogle Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• PatnaikAKangSPRascoDPhase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumorsClin Cancer Res2015214286429325977344
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• RibasAHodiSKeffordREfficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)J Clin Oncol201432suppl abstrLBA9000
   Google Scholar
• RobertCRibasAHamidOThree-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001J Clin Oncol201634 abstract9503
   Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated melanomaNew England Journal of Medicine20113642625172621639810
   PubMed Web of Science ®Google Scholar
• HodiSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaNew England Journal of Medicine201036387112320525992
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVKEYNOTE-006 InvestigatorsPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• SchachterJRibasALongAPembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006J Clin Oncol2016349504
   Google Scholar
• CurranMAMontalvoWYagitaHAllisonJPPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProc Natl Acad Sci U S A201010794275428020160101
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med20153722006201725891304
   PubMed Web of Science ®Google Scholar
• LongGVAtkinsonVCebonJSPembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohortJ Clin Oncol201634suppl abstr9506
   Google Scholar
• AndtbackaRHKaufmanHLCollichioFTalimogene laherparepvec improves durable response rate in patients with advanced melanomaJ Clin Oncol201533252780278826014293
   PubMed Web of Science ®Google Scholar
• LongGDummerRRibasAEfficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanomaJ Clin Oncol201634 abstract9568
   Web of Science ®Google Scholar
• GandadharTHamidOSmithDCEpacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202/KEYNOTE-037Ann Oncol2016271110D
   Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSTestoriALong-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaJ Clin Oncol201230313810381823008300
   PubMed Web of Science ®Google Scholar
• EggermontAMChiarion-SileniVGrobJJAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol201516552253025840693
   PubMed Web of Science ®Google Scholar
• GrossmannKFOthusMTarhiniAASWOG S1404: a phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanomaJ Clin Oncol201634supple21032
   Web of Science ®Google Scholar
• DavarDLinYKirkwoodJMUnfolding the mutational landscape of human melanomaJ Invest Dermatol2015135365966225666674
   PubMed Web of Science ®Google Scholar
• SnyderAMakarovVMerghoubTGenetic basis for clinical response to CTLA-4 blockade in melanomaN Engl J Med2014371232189219925409260
   PubMed Web of Science ®Google Scholar
• RizviNAHellmannMDSnyderACancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience2015348623012412825765070
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• TumehPCHarviewCLYearleyJHPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515752856857125428505
   PubMed Web of Science ®Google Scholar